Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
LOSARTAN POTASSIUM
B & S Healthcare
C09CA01
LOSARTAN POTASSIUM
50 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Angiotensin II antagonists, plain
Authorised
2009-06-19
PACKAGE LEAFLET: INFORMATION FOR THE USER COZAAR ® 50MG FILM-COATED TABLETS (losartan potassium) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any of the side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Cozaar 50mg film-coated tablets but it will be referred as Cozaar throughout this leaflet. Please note that this leaflet also contains information about the other strengths: Cozaar 12.5mg, 25mg and 100mg film-coated tablets. WHAT IS IN THIS LEAFLET 1. What Cozaar is and what it is used for 2. What you need to know before you take Cozaar 3. How to take Cozaar 4. Possible side effects 5. How to store Cozaar 6. Contents of the pack and other information 1. WHAT COZAAR IS AND WHAT IT IS USED FOR Losartan (Cozaar) belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure. Losartan slows the decrease of kidney function in patients with high blood pre Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cozaar 50mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 45.8 mg of losartan present as 50 mg of losartan potassium. Excipients: also includes lactose monohydrate. Each Cozaar 50mg Tablet contains 25.5mg lactose. For a full list of excipients see section 6.1 3 PHARMACEUTICAL FORM Film-coated Tablet _Product imported from UK, Poland, Spain and Italy:_ White, oval film-coated tablets with a score line on one side and ‘952’ on the other. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension in adults and in children and adolescents 6 – 18 years of age. Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria 0.5 g/day as part of an antihypertensive treatment. Treatment of chronic heart failure in adult patients when treatment with Angiotensin-converting enzyme (ACE) inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication. Patients with heart failure who have been stabilised with an ACE inhibitor should not be switched to losartan. The patients should have a left ventricular ejection fraction 40% and should be clinically stable and on an established treatment regimen for chronic heart failure. Reduction in the risk of stroke in adult hypertensive patients with left ventricular hypertrophy documented by ECG (see section 5.1 LIFE study, Race). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Hypertension The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may recei Read the complete document